Investors considering a purchase of Nymox Pharmaceutical Corp (NYMX - Get Report) shares, but cautious about paying the going market price of $4.11/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2019 put at the $3 strike, which has a bid at the time of this writing of 75 cents. Collecting that bid as the premium represents a 25% return against the $3 commitment, or a 16.2% annualized rate of return (at Stock Options Channel we call this the YieldBoost).Selling a put does not give an investor access to NYMX's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $3 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked). So unless Nymox Pharmaceutical Corp sees its shares fall 23.7% and the contract is exercised (resulting in a cost basis of $2.25 per share before broker commissions, subtracting the 75 cents from $3), the only upside to the put seller is from collecting that premium for the 16.2% annualized rate of return. Below is a chart showing the trailing twelve month trading history for Nymox Pharmaceutical Corp, and highlighting in green where the $3 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2019 put at the $3 strike for the 16.2% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Nymox Pharmaceutical Corp (considering the last 252 trading day closing values as well as today's price of $4.11) to be 112%. For other put options contract ideas at the various different available expirations, visit the NYMX Stock Options page of StockOptionsChannel.com.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Stocks
What Stocks and Sectors Investors Should Watch During the Second Half of 2019
Curious about stocks or sectors that investors should watch now that we're transitioning into the second half of 2019? Here's what Real Money contributor Stephen Guilfoyle thinks.
Facebook's Mark Zuckerberg Pushes Back on Antitrust Talk
In an interview, Zuckerberg argued that Facebook's size helps, not hinders, progress on security and other issues.
How Investors Should Approach the Trade Talks, the Federal Reserve and Micron
United States Secretary of the Treasury Steven Mnuchin made comments on the trade talks early Wednesday. Mnuchin says that he believes that the U.S. and China were almost 90% of the way through trade talks. Fed chair Jerome Powell spoke about the need for the central bank to remain independent and to not cave to "short-term political interests." And, of course, we have Micron MU, which is Real Money's stock of the day and it also released earnings Tuesday after the bell. The company beat expectations.
Ear to the Ground on UTX-Raytheon: What Needs to Happen for the Deal to Close
Shareholders are skittish about this deal, one analyst said. See why they shouldn't be.
AbbVie Rebounds as Market Warms to Allergan Deal, Botox Potential
AbbVie's deal for Allergan will give it a new revenue stream in Botox, helping offset potential lower revenue from arthritis drug Humira, which is losing patent protection.